N

    Neurocrine Biosciences Inc (NBIX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $154.03
    -0.03 (-0.02%)

    Market Cap: $15.66B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(18/40)
    Avg Surprise
    -7.29%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$2.72
    Range$2.07 - $3.39
    16 analysts
    EPS Revisions
    6
    0
    7d
    6
    7
    30d
    EPS Estimate Drift
    90d ago$3.37+23.9%
    60d ago$3.37+23.9%
    30d ago$3.23+18.8%
    7d ago$2.73+0.3%
    Current$2.72
    Revenue Consensus
    $1.0B
    Range$1.0B - $1.1B
    23 analysts
    Period ending Dec 31, 2026
    EPS Consensus$3.78
    Range$2.29 - $4.87
    16 analysts
    Revenue Consensus
    $1.2B
    Range$1.1B - $1.4B
    24 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$3.78---
    Sep 26EST
    		-$2.72---
    Jun 26
    Reported Jul 30
    		$2.36$1.88+25.53%Beat+43.0%
    Mar 26
    Reported May 5
    		$1.94$1.70+14.12%Beat+177.1%
    Dec 25
    Reported Feb 11
    		$1.88$2.30-18.26%Miss+11.2%
    Sep 25
    Reported Oct 28
    		$2.17$2.07+4.83%Beat+19.9%
    Jun 25
    Reported Jul 30
    		$1.65$1.50+10.00%Beat+1.2%
    Mar 25
    Reported May 5
    		$0.70$1.09-35.78%Miss-41.7%
    Dec 24
    Reported Feb 6
    		$1.69$1.93-12.44%Miss+9.7%
    Sep 24
    Reported Oct 30
    		$1.81$1.82-0.55%Miss+17.5%
    Jun 24
    Reported Aug 1
    		$1.63$1.53+6.54%Beat+30.4%
    Mar 24
    Reported May 1
    		$1.20$1.29-6.98%Miss+335.3%
    Dec 23
    Reported Feb 7
    		$1.54$1.51+1.99%Beat+24.2%
    Sep 23
    Reported Oct 31
    		$1.54$1.33+15.79%Beat+42.6%
    Jun 23
    Reported Aug 1
    		$1.25$1.12+11.61%Beat+48.8%
    Mar 23
    Reported May 3
    		$-0.51$0.74-168.92%Miss-270.0%
    Dec 22
    Reported Feb 6
    		$1.24$1.44-13.89%Miss+3000.0%
    Sep 22
    Reported Nov 1
    		$1.08$1.12-3.57%Miss+68.8%
    Jun 22
    Reported Aug 4
    		$0.84$0.89-5.62%Miss+33.3%
    Mar 22
    Reported May 4
    		$0.30$0.59-49.15%Miss-38.8%
    Dec 21
    Reported Feb 11
    		$0.04N/A-95.45%Miss-95.6%
    Sep 21
    Reported Nov 1
    		$0.64$0.80-20.00%Miss-34.0%
    Jun 21
    Reported Aug 3
    		$0.63$0.76-17.11%Miss-55.6%
    Mar 21
    Reported May 5
    		$0.49$0.72-31.94%Miss-40.2%
    Dec 20
    Reported Feb 4
    		$0.91$0.90+1.11%Beat+160.0%
    Sep 20
    Reported Nov 9
    		$0.97$1.25-22.40%Miss+73.2%
    Jun 20
    Reported Aug 3
    		$1.42$1.02+39.22%Beat+163.0%
    Mar 20
    Reported May 6
    		$0.82$0.64+28.13%Beat+173.2%
    Dec 19
    Reported Feb 4
    		$0.35N/A-53.33%Miss+84.2%
    Sep 19
    Reported Nov 4
    		$0.56$0.64-12.50%Miss+7.7%
    Jun 19
    Reported Jul 29
    		$0.54$0.25+116.00%Beat+871.4%
    Mar 19
    Reported Apr 29
    		$-1.12$-0.89-25.84%Miss-138.3%
    Dec 18
    Reported Feb 5
    		$0.19$0.19+0.00%Beat+171.4%
    Sep 18
    Reported Nov 5
    		$0.52$0.49+6.12%Beat+500.0%
    Jun 18
    Reported Jul 31
    		$-0.07N/A+61.11%Beat+89.7%
    Mar 18
    Reported Apr 30
    		$-0.47$-0.30-56.67%Miss+47.8%
    Dec 17
    Reported Feb 13
    		$0.07N/A-61.11%Miss+113.7%
    Sep 17
    Reported Nov 1
    		$-0.13N/A+75.47%Beat+69.8%
    Jun 17
    Reported Aug 3
    		$-0.68$-0.65-4.62%Miss-
    Mar 17
    Reported May 9
    		$-0.90$-0.72-25.00%Miss-
    Dec 16
    Reported Feb 14
    		$-0.51$-0.55+7.27%Beat-
    Sep 16
    Reported Nov 2
    		$-0.43$-0.57+24.56%Beat-

    Key Metrics

    Valuation
    P/E Ratio18.45EV/EBITDA17.21x
    Price/FCF17.97xFCF Yield5.56%
    Profitability
    Profit Margin20.90%Operating Margin22.20%
    ROE22.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage3.85x
    Current Ratio1.87xQuick Ratio1.75x
    Trading Statistics
    Beta0.39Avg Volume1.22M
    52-Week High$186.1252-Week Low$122.14

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$154.23
    SMA 20$156.72
    SMA 50$166.36
    SMA 200$147.29
    EMA 10$155.04
    EMA 20$157.80
    EMA 50$160.92
    EMA 200$149.93

    MACD

    Line: -3.69Signal: -3.95Hist: 0.26

    ADX

    ADX: 29.6+DI: 15.4-DI: 25.9

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down56.0
    PSAR$149.40

    Bollinger Bands

    Upper Band$165.83
    Lower Band$147.62
    %B Position1162%(Upper)
    Band Width0.35

    RSI (14-Day)

    Neutral
    40.4

    Momentum Oscillators

    Stoch %K40.5
    Stoch %D40.0
    Williams %R-53.1
    ROC (10d)-0.3%
    Momentum-0.46
    CCI (20d)-57.5
    MFI (14d)31.6

    Volatility Measures

    ATR (14d)$4.51(2.9%)
    StdDev (20d)4.55
    Hist Vol26.3%(Moderate)

    Volume Flow

    VWAP$153.60
    OBV35.3M
    AD Line14.5M
    CMF (20d)-0.183

    Volume Metrics

    Avg Vol (20d)1.2M
    Vol Ratio1.4x
    VWMA (20d)$156.38

    Pivot Points

    R3$159.55
    R2$158.06
    R1$156.06
    Pivot Point$154.57
    S1$152.57
    S2$151.08
    S3$149.08

    Advanced Oscillators

    TSI-20.38
    Ultimate Osc44.5
    KST-101.02

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$959.00M$814.50M$805.50M$794.90M$687.50M$572.60M$627.70M$622.10M$590.20M$515.30M$515.20M$498.80M
    Cost of Revenue$0$13.80M$17.60M$14.00M$10.30M$9.20M$9.30M$8.00M$9.20M$7.50M$8.50M$11.20M
    Gross Profit$959.00M$800.70M$787.90M$780.90M$677.20M$563.40M$618.40M$614.10M$581.00M$507.80M$506.70M$487.60M
    Operating Expenses$807.50M$607.30M$577.00M$541.90M$531.60M$539.80M$476.40M$430.30M$435.60M$408.50M$356.40M$346.40M
    R&D$328.20M$317.40M$275.20M$250.30M$244.30M$263.30M$188.60M$196.00M$193.60M$165.40M$137.50M$142.20M
    SG&A$439.70M$318.50M$301.80M$291.60M$286.30M$276.50M$287.80M$234.30M$242.00M$243.10M$218.90M$204.20M
    Operating Income$151.50M$193.40M$210.90M$239.00M$145.60M$23.60M$142.00M$183.80M$145.40M$99.30M$150.30M$141.20M
    Interest Income$12.40M$28.10M$25.80M$22.20M$0$21.70M$22.50M$23.40M$22.80M$22.30M$17.80M$14.50M
    Interest Expense$2.90M$0$0$0$0$8.90M$0$0$49.70M$88.70M$-1,100,000$0
    Income Before Tax$162.20M$246.80M$239.40M$291.80M$159.50M$14.70M$162.60M$190.30M$98.60M$34.50M$198.20M$115.60M
    Income Tax Expense$17.80M$48.90M$85.70M$82.30M$52.00M$6.80M$59.50M$60.50M$33.60M$-8,900,000$50.50M$32.50M
    Net Income$144.40M$197.90M$153.70M$209.50M$107.50M$7.90M$103.10M$129.80M$65.00M$43.40M$147.70M$83.10M
    EBITDA$180.20M$224.70M$219.10M$274.60M$163.40M$-4,000,000$141.60M$166.90M$125.80M$100.00M$178.70M$100.60M
    EBIT$152.70M$218.70M$213.60M$269.60M$159.50M$-7,000,000$140.10M$166.90M$125.50M$100.90M$179.30M$101.10M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NBIX

    News

    Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition

    Nxera Pharma's partner Neurocrine Biosciences has received FDA IND acceptance for a Phase 2 study of NBI-1117567 for Alzheimer's cognition. Nxera Pharma will receive a $10 million milestone payment as a result. NBI-1117567 is an oral, muscarinic M1 preferring (M1/M4) selective agonist, part of a broader collaboration between the two companies to develop muscarinic receptor agonists for neuropsychiatric disorders.

    Yahoo Finance•8/26/26•
    Bullish

    Neurocrine Biosciences (NBIX) Stock Still Looks Like A Bargain Following Its 59% Run

    Neurocrine Biosciences (NBIX) stock has seen a 59% return over the past five years but remains undervalued according to Simply Wall St's metrics. Its current P/E ratio of 22.0x is below the industry peer average and a tailored fair multiple, suggesting the market isn't fully pricing in its potential. The company's future stock performance hinges on its earnings and cash flow development from key drugs like INGREZZA, alongside managing clinical, regulatory, and competitive risks.

    Simply Wall Street•8/24/26•
    Bullish

    Neurocrine Biosciences (NBIX) Stock Still Looks Like A Bargain Following Its 59% Run

    Neurocrine Biosciences (NBIX) stock has seen a 59% return over five years but still appears undervalued based on its current P/E ratio compared to its tailored fair multiple and industry peers. Despite positive attention from new study results for INGREZZA, the market is not yet fully pricing in a premium, suggesting potential for further upside if earnings and cash flow from key drugs continue to develop favorably.

    Simply Wall Street•8/24/26•
    Somewhat-Bullish

    Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    Neurocrine Biosciences (NBIX) is expected to report significant year-over-year growth in earnings and revenues for the quarter ended June 2026, with analysts forecasting $2.24 EPS and $894.32 million in revenue. The company has a Zacks Rank #1 (Strong Buy) and a positive Earnings ESP of +3.77%, suggesting a high probability of beating consensus EPS estimates. Investors will be watching the July 30 release closely, as NBIX has historically beaten EPS estimates in three of the last four quarters.

    Eastern Progress•8/22/26•
    Bullish

    Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates

    Neurocrine Biosciences (NBIX) reported Q1 earnings of $1.94 per share, surpassing the Zacks Consensus Estimate of $1.68 and significantly up from $0.08 a year ago. The company also exceeded revenue expectations, posting $814.5 million against an estimate of $741.8 million. Despite underperforming the S&P 500 year-to-date, Neurocrine currently holds a Zacks Rank #2 (Buy), indicating expected market outperformance.

    Eastern Progress•8/22/26•
    Bullish

    Frequently Asked Questions About NBIX

    Does NBIX pay dividends?
    Neurocrine Biosciences Inc (NBIX) does not currently pay a regular dividend.
    What is NBIX's P/E ratio?
    Neurocrine Biosciences Inc has a price-to-earnings (P/E) ratio of 18.45.
    What is NBIX's market cap?
    Neurocrine Biosciences Inc (NBIX) has a market capitalization of $15.66B with a current stock price of $154.03.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In